In addition, recurrent gene fusions have been discovered in a variety of epithelial tumors, such as prostate, lung, stomach and colorectal cancers and some of the fusion genes have been confirmed to be ideal molecular targets for cancer therapy, as the EML4-ALK fusion gene in non-small-cell lung cancer [41–47]. Here, ALK is linked to colorectal cancer.